Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
IPO Year: 2019
Exchange: NASDAQ
Website: gossamerbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/25/2024 | $9.00 | Outperform | Oppenheimer |
| 4/5/2024 | $4.00 | Outperform | Wedbush |
| 7/27/2023 | $8.00 → $1.25 | Buy → Neutral | UBS |
| 3/7/2023 | Outperform → Mkt Perform | Raymond James | |
| 3/1/2023 | Neutral | Guggenheim | |
| 12/7/2022 | Neutral → Underweight | JP Morgan | |
| 12/7/2022 | $3.00 | Outperform → Neutral | SMBC Nikko |
| 12/7/2022 | $18.00 → $2.00 | Overweight → Equal Weight | Barclays |
| 10/20/2022 | $22.00 | Buy | Goldman |
| 9/21/2022 | $17.00 | Neutral | JP Morgan |
Oppenheimer initiated coverage of Gossamer Bio with a rating of Outperform and set a new price target of $9.00
Wedbush resumed coverage of Gossamer Bio with a rating of Outperform and set a new price target of $4.00
UBS downgraded Gossamer Bio from Buy to Neutral and set a new price target of $1.25 from $8.00 previously
Raymond James downgraded Gossamer Bio from Outperform to Mkt Perform
Guggenheim initiated coverage of Gossamer Bio with a rating of Neutral
JP Morgan downgraded Gossamer Bio from Neutral to Underweight
SMBC Nikko downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $3.00
Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $2.00 from $18.00 previously
Goldman initiated coverage of Gossamer Bio with a rating of Buy and set a new price target of $22.00
JP Morgan initiated coverage of Gossamer Bio with a rating of Neutral and set a new price target of $17.00
- Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that, Bryan Giraudo has been appointed Chief Operating Officer, in addition to his continued role as Chief Financial Officer. Mr. Giraudo joined Gossamer in May 2018 as its Chief Financial Officer. "Bryan has been instrumental in strengthening the financial and organizational foundation of the Company," said Faheem Hasnain, Chairman, co-founder and CEO of Gossamer Bio. "Since his arrival at Gossamer, his responsibilities have extended far beyond just the fina
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the appointment of Sandra Milligan, M.D., J.D., to its Board of Directors. "It is an honor to welcome Dr. Sandra Milligan to the Gossamer Bio team," said Faheem Hasnain, Chairman, President and CEO of Gossamer Bio. "Dr. Milligan has a wealth of experience and knowledge that will be invaluable to Gossamer's ongoing efforts to deliver novel therapies to patients in need. The rest of the Board of Directors and I look forward to collaborating closely with her."
MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba
MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the
- Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - To Date, Blinded Baseline Characteristics Align with Intended Study Population - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash equivalents and marketable securities totaled $258 million as of March 31, 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmona
Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, May 15, 2025, to discuss the Company's financial results and provide a corporate update. Domestic Dial-in Number: (800) 285-6670 International Dial-in Number: (713) 4
Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 258,750 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an induceme
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, California. Poster Presentation Title: Seralutinib in Pulmonary Arterial Hypertension: Exploring Mechanisms of Reverse Remodeling Versus Vasodilation Poster Number: P920 Session: A76 Finger on the Pulse: Cardiopulmonary Dysfunction in
Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective April 7, 2025, to one non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 55,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an inducement
- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation for PAH in Japan - - Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December
Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective March 5, 2025, to five non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 342,250 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an inducem
MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt
- Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - To Date, Blinded Baseline Characteristics Align with Intended Study Population - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash equivalents and marketable securities totaled $258 million as of March 31, 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmona
Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, May 15, 2025, to discuss the Company's financial results and provide a corporate update. Domestic Dial-in Number: (800) 285-6670 International Dial-in Number: (713) 4
- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation for PAH in Japan - - Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December
- $327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. "Looking forward, we expect 2025 to be an exceptionally important year for Gossamer, as we both anticipate Phase 3 PROSERA Study results in PAH and commence our PH-ILD Phase 3 study," said Faheem Hasnain, Co-
- $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2024 and provided a business update. "Between the continued progress made in the enrollment of the Phase 3 PROSERA Study and the transformational collaboration agreement with the Chiesi Group, Gossamer has made great strides in the second quarter to ad
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet Respiratory Medicine - - Latest PAH Open-Label Extension Dataset to be Presented at ATS in San Diego on May 19th - - $396 Million in Cash, Cash Equivalents & Marketable Securities, as of March 31, 2024, Pro Forma for $160 Million Reimbursement Payment and Debt Repayment - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib
- Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones - - Gossamer leading US commercialization activities in PAH and PH-ILD; 50 / 50 commercial profit split in US and global development cost sharing arrangement - - Chiesi, a global leader in the pulmonary and rare disease spaces, obtains exclusive ex-US commercial rights, with Gossamer to receive mid-to-high teens royalties on net sales - - Gossamer and Chiesi plan to initiate Phase 3 Trial of Seralutinib in PH-ILD in Mid-2025 - Gossamer Bio, Inc. ("Gossamer") (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused
- First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance by PMDA - - Cash, cash equivalents and marketable securities totaled $296 million at year-end 2023 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update. "We were thrilled to enroll the first patient in the registrational PROSERA Study last year, and we are pleased wit
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension. The live audio webcast may be accessed throu
- Phase 3 PROSERA Site Activations Proceeding Ahead of Schedule; First Dosing Expected in 4Q23 - - Additional Data from TORREY Open-Label Extension Expected in 4Q23 - - $329 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2023 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the third quarter ended September 30, 2023, and provided a business update. "We are pleased with the progress our team has made with the launch of the seralutinib Phase 3 PROSERA Study. Wi
Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
8-K - Gossamer Bio, Inc. (0001728117) (Filer)
10-Q - Gossamer Bio, Inc. (0001728117) (Filer)
DEFA14A - Gossamer Bio, Inc. (0001728117) (Filer)
DEF 14A - Gossamer Bio, Inc. (0001728117) (Filer)
S-8 - Gossamer Bio, Inc. (0001728117) (Filer)
8-K - Gossamer Bio, Inc. (0001728117) (Filer)
10-K - Gossamer Bio, Inc. (0001728117) (Filer)
8-K - Gossamer Bio, Inc. (0001728117) (Filer)
SCHEDULE 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
8-K - Gossamer Bio, Inc. (0001728117) (Filer)
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13D - Gossamer Bio, Inc. (0001728117) (Subject)